alstria office REIT-AG Valuation
Is 0O9Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0O9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0O9Q (€7) is trading below our estimate of fair value (€7.23)
Significantly Below Fair Value: 0O9Q is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0O9Q?
Key metric: As 0O9Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0O9Q's PS Ratio? | |
|---|---|
| PS Ratio | 5.2x |
| Sales | €240.21m |
| Market Cap | €1.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.9x |
| Enterprise Value/EBITDA | 19.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0O9Q's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.4x | ||
WKP Workspace Group | 5.6x | -1.9% | UK£1.0b |
GPE Great Portland Estates | 8.1x | 1.7% | UK£1.2b |
GWI Globalworth Real Estate Investments | 3.2x | n/a | €746.8m |
DLN Derwent London | 8.5x | -1.4% | UK£2.4b |
0O9Q alstria office REIT-AG | 5.2x | -1.5% | €1.2b |
Price-To-Sales vs Peers: 0O9Q is good value based on its Price-To-Sales Ratio (5.2x) compared to the peer average (6.4x).
Price to Sales Ratio vs Industry
How does 0O9Q's PS Ratio compare vs other companies in the European Office REITs Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0O9Q is good value based on its Price-To-Sales Ratio (5.2x) compared to the European Office REITs industry average (8.3x).
Price to Sales Ratio vs Fair Ratio
What is 0O9Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.2x |
| Fair PS Ratio | 4.7x |
Price-To-Sales vs Fair Ratio: 0O9Q is expensive based on its Price-To-Sales Ratio (5.2x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €7.00 | €7.30 +4.3% | 2.7% | €7.50 | €7.10 | n/a | 2 |
| Nov ’25 | €6.74 | €5.45 -19.1% | 37.6% | €7.50 | €3.40 | n/a | 2 |
| Oct ’25 | €5.96 | €5.45 -8.6% | 37.6% | €7.50 | €3.40 | n/a | 2 |
| Sep ’25 | €3.52 | €5.55 +57.7% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Aug ’25 | €3.52 | €5.55 +57.7% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Jul ’25 | €3.38 | €5.55 +64.2% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Jun ’25 | €3.57 | €5.55 +55.5% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| May ’25 | €3.65 | €5.55 +52.1% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Apr ’25 | €3.30 | €5.55 +68.2% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Mar ’25 | €3.64 | €5.55 +52.5% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Feb ’25 | €3.55 | €5.55 +56.6% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Jan ’25 | €3.66 | €5.55 +51.8% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Dec ’24 | €4.65 | €5.55 +19.4% | 35.1% | €7.50 | €3.60 | n/a | 2 |
| Nov ’24 | €3.50 | €7.45 +112.6% | 0.7% | €7.50 | €7.40 | €6.74 | 2 |
| Oct ’24 | €3.69 | €7.45 +101.9% | 0.7% | €7.50 | €7.40 | €5.96 | 2 |
| Sep ’24 | €4.75 | €7.45 +56.8% | 0.7% | €7.50 | €7.40 | €3.52 | 2 |
| Aug ’24 | €4.97 | €13.70 +175.4% | 46.0% | €20.00 | €7.40 | €3.52 | 2 |
| Jul ’24 | €4.99 | €13.70 +174.5% | 46.0% | €20.00 | €7.40 | €3.38 | 2 |
| Jun ’24 | €5.02 | €13.70 +172.9% | 46.0% | €20.00 | €7.40 | €3.57 | 2 |
| May ’24 | €5.89 | €14.75 +150.4% | 35.6% | €20.00 | €9.50 | €3.65 | 2 |
| Apr ’24 | €6.11 | €14.75 +141.5% | 35.6% | €20.00 | €9.50 | €3.30 | 2 |
| Mar ’24 | €7.52 | €15.00 +99.6% | 28.7% | €20.00 | €9.50 | €3.64 | 3 |
| Feb ’24 | €7.61 | €15.00 +97.2% | 28.7% | €20.00 | €9.50 | €3.55 | 3 |
| Jan ’24 | €7.79 | €15.00 +92.6% | 28.7% | €20.00 | €9.50 | €3.66 | 3 |
| Dec ’23 | €7.31 | €15.00 +105.3% | 28.7% | €20.00 | €9.50 | €4.65 | 3 |
| Nov ’23 | €8.77 | €16.03 +82.9% | 19.0% | €20.00 | €12.60 | €3.50 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Cofinimmo
€2.1b
Cofinimmo has been acquiring, developing and managing rental properties for 40 years.
0J3X
€56.26
7D
-1.6%
1Y
-13.1%
Xior Student Housing
€1.3b
Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden.
0RD8
€30.80
7D
1.8%
1Y
-0.9%
Care REIT
UK£348.1m
Impact Healthcare REIT plc acquires, renovates, extends and redevelops high quality healthcare real estate assets in the UK and lets these assets on long-term full repairing and insuring leases to high-quality established healthcare operators which offer good quality care, under leases which provide the Company with attractive levels of rent cover.
CRT
UK£0.84
7D
2.9%
1Y
-1.5%